Human Cell Liver Models Flag Drug Toxicity

✓ Medically reviewed | Published: | Evidence level: 1A
Drug-induced liver injury is a leading reason drug candidates fail and approved drugs are withdrawn, and animal studies do not always predict it in people. A company reported that its human-cell liver model flagged liver risks in 10 candidates that animal studies had missed. The result is promising but comes from a company announcement, so independent validation is needed.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pharmacology

Quick Facts

Reported Result
10 of 10 flagged
Organ at Issue
Liver (hepatotoxicity)
Evidence Status
Company-reported, needs validation

Why do animal studies miss liver toxicity in some drugs?

Quick answer: Animals differ from humans in drug metabolism, immune responses and liver biology, so a drug that looks safe in animals can still injure the human liver.

Drug-induced liver injury (DILI) is one of the most common safety reasons that drug candidates are stopped during development, and it is a recurring cause of post-approval warnings and market withdrawals. The liver is the main site of drug metabolism. Small species differences in enzymes such as the cytochrome P450 family, in transporters and in bile acid handling can change how much of a toxic metabolite forms. Some forms of liver injury are also idiosyncratic. They depend on a person's genetics or immune response and are rare enough to escape detection in small animal groups.

Preclinical toxicology has long relied on rodents and a second species such as dogs or non-human primates. These studies are valuable for many risks, but they have known blind spots. A compound that is harmless in a rat can produce serious liver injury in people, and the reverse also occurs. The practical effect is that some hepatotoxicity is only discovered in human trials, after participants have already been exposed.

What did the human-cell liver model reportedly show?

Quick answer: According to a company announcement covered by Stock Titan, VivoSim's human-cell model flagged liver risk in all 10 drug candidates that animal studies had missed.

The report describes a human-cell-based liver model that identified liver safety concerns in 10 drug candidates for which animal studies had not shown the same risk. These platforms use human liver cells, often in three-dimensional or tissue-like formats, to better capture human-specific metabolism and toxicity. The result comes from a company announcement rather than a peer-reviewed publication, so readers should treat it as an encouraging signal rather than proof.

Several questions matter when judging claims like this. How were the 10 compounds chosen, and were they selected because they were already known to cause human liver injury? How often does the model flag safe drugs as toxic? How does it perform across drug classes and liver injury mechanisms? A model that flags every compound can look perfect on a set of known toxic drugs yet be of little use if it also over-flags safe ones. Independent testing with blinded compounds is the stronger standard.

How could human-based models change drug development and regulation?

Quick answer: They could help screen out risky compounds earlier, and regulators are increasingly open to non-animal methods, but these models are likely to complement animal and clinical data rather than replace them soon.

In the United States, the FDA Modernization Act 2.0, signed in December 2022, removed the statutory requirement that drug safety testing use animals and allowed validated alternatives such as cell-based assays and computational models. The FDA has since publicly signaled a push to reduce reliance on animal testing, particularly for some antibody-based drugs. Human-cell liver models, organ-on-chip systems and in silico tools are central to that shift.

For patients, the potential benefit is fewer people exposed to compounds likely to harm the liver, plus fewer promising drugs abandoned because of misleading animal findings. Adoption depends on formal validation, consistent standards and regulatory acceptance. In the near term, developers are likely to use human-cell models alongside conventional toxicology and careful liver monitoring in early clinical trials.

Frequently Asked Questions

Drug-induced liver injury is damage to the liver caused by a medicine or supplement. It ranges from mild enzyme elevations to acute liver failure. Symptoms can include fatigue, nausea, dark urine and yellowing of the skin or eyes, which should prompt medical attention.

Not yet. Regulators have opened the door to validated non-animal methods, but human-cell models are mostly used to complement animal and clinical data while they are validated further.

Approved medicines go through clinical trials and ongoing safety monitoring. Patients should not stop prescribed medicines on their own, and should report symptoms of liver trouble to a clinician promptly.

References

  1. Stock Titan. Animal studies missed liver risks in 10 drug candidates. VivoSim's human-cell model flagged all 10. November 2026.
  2. U.S. Food and Drug Administration. FDA Modernization Act 2.0 and nonclinical testing alternatives.
  3. U.S. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.